NORWALK, CT, Oct. 30, 2009 (Marketwire) --
NORWALK, CT -- (Marketwire) -- 10/30/09 -- Elsevier Business Intelligence and Windhover Conferences have announced their complete Top 10 Projects to Watch for the upcoming Therapeutic Area Partnerships event, Nov. 17-19 in Boston, MA. This year's list will offer a Top 10 in each of four therapeutic areas: cardiovascular/metabolic, oncology, neuroscience and inflammatory/autoimmune. Past Windhover top 10 candidates signed a total potential value of $17 billion US in acquisitions and alliances. Confirmed participating companies include Lundbeck, Astellas, Biovail, Bristol-Myers Squibb, Biogen Idec, Millennim, Merck, Novartis, Eli Lilly, Genzyme, Merck and Company, Wyeth, GlaxoSmithKline, Merck Serono, Daiichi Sankyo, and AstraZeneca.
Complete details of all projects to date are available at http://www.tapartnerships.com?goto=content/tb_schedule.aspx. Each project has been hand-selected by Windhover's elite selection panel to ensure a high-quality slate of presenters. The projects have met rigorous criteria including: unmet medical need, market potential, diversity of indications, strong science, multi-level partnering opportunities (biotech and pharma), potential for new opportunities beyond initial indications, and corporate stability.
Oncology companies on the list are TransMolecular, AngioChem, Ariad, Allos, Gloucester, Oncothyreon, Rexahn, Biothera, Infinity Pharmaceuticals and Cornerstone Pharmaceuticals.
Cardiovascular/metabolic companies are Aryx, XOMA, Array Biopharma, TransTech Pharma, Zafgen, Vitae, Galmed Medical Research, Celladon, Metabolex and Alnylam.
Neuroscience companies are EnVivo Pharmaceuticals Inc., NeurAxon Inc., Allon Therapeutics, Alexza, AFRAXIS, Karo Bio, CeNeRx, Trophos, Prana Biotechnology and Braincells.
Inflammatory/autoimmune companies are Enzo Biochem, Almirall, Orexo, Galactica Pharmaceuticals, Bayhill Therapeutics, Chelsea Therapeutics, LifeCycle Pharma, Lexicon Pharmaceuticals, and Synta Pharmaceuticals.
Companies will present the product's target and first indication(s); other compounds addressing the same target; the relative advantage of the compound; the clinical results to date and general clinical plan for the future; IP on the compound or target; and any partnerships the company currently holds on the compound.
